BACKGROUND: Cancer patients usually take many medications. The proportion of patients with advanced cancer who are taking futile drugs is unknown. MATERIALS AND METHODS: We retrospectively reviewed the charts of all consecutive ambulatory patients with advanced cancer and who were receiving supportive care exclusively at palliative care clinics, Princess Margaret Hospital, to gather information on futile medications used by them. Futile medications were defined as unnecessary (when no short-term benefit to patients with respect to survival, quality of life, or symptom control was anticipated) or duplicate (two or more drugs from the same pharmacological class). Summary statistics were used to describe the results. RESULTS: From November 2005 to July 2006, 82 (22%) of 372 patients were taking at least one futile medication before consultation; after initial consultation, this proportion dropped to 20% (78): 70 patients were taking unnecessary medications, while eight were on duplicate medications. The most frequent unnecessary medications used by patients were statins (56%). The most common duplicate medication involved the use of two different benzodiazepines (seven patients). CONCLUSION: About one fifth of cancer outpatients at the end of life take futile medications, most commonly statins. Prospective and population-based studies are warranted to further evaluate the magnitude and consequences of futile medication use in oncology.
BACKGROUND:Cancerpatients usually take many medications. The proportion of patients with advanced cancer who are taking futile drugs is unknown. MATERIALS AND METHODS: We retrospectively reviewed the charts of all consecutive ambulatory patients with advanced cancer and who were receiving supportive care exclusively at palliative care clinics, Princess Margaret Hospital, to gather information on futile medications used by them. Futile medications were defined as unnecessary (when no short-term benefit to patients with respect to survival, quality of life, or symptom control was anticipated) or duplicate (two or more drugs from the same pharmacological class). Summary statistics were used to describe the results. RESULTS: From November 2005 to July 2006, 82 (22%) of 372 patients were taking at least one futile medication before consultation; after initial consultation, this proportion dropped to 20% (78): 70 patients were taking unnecessary medications, while eight were on duplicate medications. The most frequent unnecessary medications used by patients were statins (56%). The most common duplicate medication involved the use of two different benzodiazepines (seven patients). CONCLUSION: About one fifth of cancer outpatients at the end of life take futile medications, most commonly statins. Prospective and population-based studies are warranted to further evaluate the magnitude and consequences of futile medication use in oncology.
Authors: Camilla Zimmermann; Dori Seccareccia; Allyson Clarke; David Warr; Gary Rodin Journal: Support Care Cancer Date: 2006-06-27 Impact factor: 3.603
Authors: E S T Samano; L M Ribeiro; A S Campos; F Lewin; E S V Filho; P T Goldenstein; L J M Costa; A del Giglio Journal: Eur J Cancer Care (Engl) Date: 2005-05 Impact factor: 2.520
Authors: Eliana Sueco Tibana Samano; Patricia Taschner Goldenstein; Lia de Melo Ribeiro; Fabio Lewin; Edgar Santiago Valesin Filho; Heloisa Prado Soares; Auro del Giglio Journal: Sao Paulo Med J Date: 2004-07-05 Impact factor: 1.044
Authors: Rachel P Riechelmann; Ian F Tannock; Lisa Wang; Everardo D Saad; Nathan A Taback; Monika K Krzyzanowska Journal: J Natl Cancer Inst Date: 2007-04-18 Impact factor: 13.506
Authors: N J H Raijmakers; L van Zuylen; C J Furst; M Beccaro; L Maiorana; P Pilastri; C Rossi; G Flego; A van der Heide; M Costantini Journal: Support Care Cancer Date: 2012-10-14 Impact factor: 3.603
Authors: Justin P Turner; Sepehr Shakib; Nimit Singhal; Jonathon Hogan-Doran; Robert Prowse; Sally Johns; J Simon Bell Journal: Support Care Cancer Date: 2014-03-02 Impact factor: 3.603
Authors: Thuy Koll; Mackenzi Pergolotti; Holly M Holmes; Huibrie C Pieters; G J van Londen; Zachary A Marcum; Amy R MacKenzie; Christopher B Steer Journal: Curr Oncol Rep Date: 2016-08 Impact factor: 5.075